# Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

> **NCT02076594** · PHASE3 · TERMINATED · sponsor: **Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente** · enrollment: 171 (actual)

## Conditions studied

- Locally Advanced Unresectable Gastric Cancer
- Metastatic Gastric Cancer

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Epirubicin
- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02076594
- **Lead sponsor:** Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12-31
- **Target enrollment:** 171 (ACTUAL)
- **Why stopped:** The interim analysis performed on 09 November 2018, showed the failure to achieve the primary objective of effectiveness of the experimental treatment.
- **Last updated:** 2019-10-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02076594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02076594, "Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02076594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*